Federal Register / Vol. 70, No.

170 / Friday, September 2, 2005 / Notices 52405

inhibitors in vitro and can be used to resistant mutants of HIV–1 RT. Please additional information about RT
test drug candidates for their contact Dr. Hughes directly expression plasmids that are not listed
effectiveness against common drug (hughes@ncifcrf.gov) if you want below.

Vector Description Reference No.

Wild-type HIV–1 RT ................................................................. full length, wild type ................................................................. E–034–1991/0

L100I ........................................................................................
K103N ......................................................................................
V106A ......................................................................................
V108I ........................................................................................
E138K ......................................................................................
Y181I ........................................................................................
Y181C ......................................................................................
Y188L .......................................................................................
Y188H ......................................................................................
G190A ......................................................................................
G190S ......................................................................................
P236L .......................................................................................
NNRTI resistant ....................................................................... E–034–1991/1
NNRTI resistant ....................................................................... E–034–1991/1
NNRTI resistant ....................................................................... E–034–1991/1
.................................................................................................. ..............................
NNRTI resistant ....................................................................... E–034–1991/1
.................................................................................................. ..............................
NNRTI resistant ....................................................................... E–034–1991/1
.................................................................................................. ..............................
NNRTI resistant ....................................................................... E–034–1991/1
.................................................................................................. ..............................
.................................................................................................. ..............................
NNRTI resistant ....................................................................... E–034–1991/1

RTs that carry some combinations of NNRTI mutations, e.g., K103N+Y181I, are also available.

K65R ........................................................................................ NRTI resistant ......................................................................... E–034–1991/2

T69G ........................................................................................
L74V .........................................................................................
M184I .......................................................................................
M184V ......................................................................................
AZT–R (5 mutations) ...............................................................
D67 complex ............................................................................
Q151M .....................................................................................
Q151M Complex ......................................................................
SSGR/T215Y ...........................................................................
SSSR/T215Y ............................................................................
.................................................................................................. ..............................
NRTI resistant ......................................................................... E–034–1991/1
Lamivudine (3TC) resistant ..................................................... ..............................
Lamivudine (3TC) resistant ..................................................... E–034–1991/1
AZT resistant ........................................................................... E–034–1991/1
Multi-NRTI resistant ................................................................. E–034–1991/4
Multi-NRTI resistant ................................................................. E–034–1991/4
Multi-NRTI resistant ................................................................. E–034–1991/4
Multi-NRTI resistant ................................................................. E–034–1991/4
Multi-NRTI resistant ................................................................. E–034–1991/4

Dated: August 20, 2005. the discussions could disclose applicable, the business or professional
Steven M. Ferguson, confidential trade secrets or commercial affiliation of the interested person.
Director, Division of Technology Development property such as patentable material, Dated: August 25, 2005.
and Transfer, Office of Technology Transfer, and personal information concerning Anthony M. Coelho, Jr.,
National Institutes of Health. individuals associated with the grant Acting Director, Office of Federal Advisory
[FR Doc. 05–17517 Filed 9–1–05; 8:45 am] applications, the disclosure of which Committee Policy.
BILLING CODE 4140–01–P would constitute a clearly unwarranted [FR Doc. 05–17514 Filed 9–1–05; 8:45 am]
invasion of personal privacy. BILLING CODE 4140–01–M
Name of Committee: National Advisory
DEPARTMENT OF HEALTH AND Council on Minority Health and Health
HUMAN SERVICES Disparities. DEPARTMENT OF HEALTH AND
Date: September 20, 2005. HUMAN SERVICES
National Institutes of Health Closed: 8:30 a.m. to 10 a.m.
Agenda: To review and evaluate grant National Institutes of Health
National Center on Minority Health and applications and/or proposals.
Health Disparities; Notice of Meeting Place: National Institutes of Health, Two National Eye Institute; Notice of
Democracy Plaza, 6707 Democracy
Pursuant to section 10(d) of the Boulevard, Suite 800, Bethesda, MD 20892. Meeting
Federal Advisory Committee Act, as Open: 10:30 a.m. to 5:30 p.m.
amended (5 U.S.C. Appendix 2), notice Agenda: The agenda will include Opening
Pursuant to section 10(d) of the
is hereby given by the National Remarks, Administrative Matters, Director’s Federal Advisory Committee Act, as
Advisory Council on Minority Health Report, NCMHD, IC Health Disparities amended (5 U.S.C. Appendix 2), notice
and Health Disparities. Research Report, NCMHD Program is hereby given of a meeting of the
The meeting will be open to the Highlights, and other business of the Council. National Advisory Eye Council.
Place: National Institutes of Health, Two The meeting will be open to the
public as indicated below, with Democracy Plaza, 6707 Democracy
attendance limited to space available. Boulevard, Suite 800, Bethesda, MD 20892.
public as indicated below, with
Individuals who plan to attend and Contact Person: Donna Brooks, Asst. attendance limited to space available.
need special assistance, such as sign Director for Administration, National Center Individuals who plan to attend and
language interpretation or other on Minority Health and Health Disparities, need special assistance, such as sign
reasonable accommodations, should National Institutes of Health, 6707 language interpretation or other
notify the Contact Person listed below Democracy Blvd., Suite 800, Bethesda, MD reasonable accommodations, should
20892, 301–435–2135, notify the Contact Person listed below
in advance of the meeting.
brooksd@ncmhd.nih.gov. in advance of the meeting.
The meeting will be closed to the Any interested person may file written
public in accordance with the comments with the committee by forwarding The meeting will be closed to the
provisions set forth in sections the statement to the Contact Person listed on public in accordance with the
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., this notice. The statement should include the provisions set forth in sections
as amended. The grant applications and name, address, telephone number and when 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

VerDate Aug<18>2005 18:00 Sep 01, 2005 Jkt 205001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\02SEN1.SGM 02SEN1